| 00:00:00 | Welcome |
| 00:00:11 | Introduction |
| 00:02:01 | Viscosizer TD:Protein Stability Characterization Platform |
| 00:02:06 | Untitled |
| 00:02:17 | Untitled |
| 00:02:28 | Untitled |
| 00:02:40 | Emerging Market - Towards novel biologics |
| 00:03:14 | Emerging Market - Towards novel biologics |
| 00:03:58 | Untitled |
| 00:04:10 | Untitled |
| 00:04:29 | Untitled |
| 00:04:47 | Protein stability profiling |
| 00:04:59 | Protein stability profiling |
| 00:05:25 | Viscosizer TD – Physical stability profiling |
| 00:05:47 | Viscosizer TD – Physical stability profiling |
| 00:06:05 | Viscosizer TD – Physical stability profiling |
| 00:06:15 | Untitled |
| 00:06:48 | Viscosizer TD – Instrument |
| 00:07:04 | Viscosizer TD – Instrument |
| 00:07:37 | Viscosizer TD – Instrument |
| 00:08:04 | Viscosizer TD – Instrument |
| 00:08:32 | Viscosizer TD – Instrument |
| 00:08:45 | Taylor Dispersion Analysis – Size |
| 00:09:05 | Taylor Dispersion Analysis – Size |
| 00:09:55 | Taylor Dispersion Analysis – Size |
| 00:10:22 | Untitled |
| 00:10:57 | Untitled |
| 00:11:57 | Untitled |
| 00:12:44 | Untitled |
| 00:13:00 | Taylor Dispersion Analysis – kD |
| 00:14:28 | Untitled |
| 00:15:40 | Untitled |
| 00:16:32 | Poiseuille Flow – Viscosity |
| 00:16:47 | Poiseuille Flow – Viscosity |
| 00:17:01 | Poiseuille Flow – Viscosity |
| 00:17:04 | Poiseuille Flow – Viscosity |
| 00:17:06 | Poiseuille Flow – Viscosity |
| 00:17:10 | Poiseuille Flow – Viscosity |
| 00:17:24 | Poiseuille Flow – Viscosity |
| 00:17:29 | Untitled |
| 00:17:42 | Measurement Capabilities |
| 00:17:56 | Measurement Capabilities |
| 00:18:01 | Measurement Capabilities |
| 00:18:20 | Untitled |
| 00:18:40 | Applications: Early developability screen of mAb candidates using TDA |
| 00:19:21 | Applications: Early developability screen of mAb candidates using TDA |
| 00:19:41 | Applications: Early developability screen of mAb candidates using TDA |
| 00:19:59 | Applications: Early developability screen of mAb candidates using TDA |
| 00:20:33 | Applications: Early developability screen of mAb candidates using TDA |
| 00:20:38 | Applications: Early developability screen of mAb candidates using TDA |
| 00:20:43 | Applications: DLS vs. TDA for characterisation of peptide and protein aggregates |
| 00:20:58 | Applications: DLS vs. TDA for characterisation of peptide and protein aggregates |
| 00:21:36 | Applications: DLS vs. TDA for characterisation of peptide and protein aggregates |
| 00:22:23 | Applications: DLS vs. TDA for characterisation of peptide and protein aggregates |
| 00:22:28 | Applications: Peptide- peptide interaction analysis using TDA |
| 00:23:23 | Applications: Peptide- peptide interaction analysis using TDA |
| 00:23:31 | Applications: Aggregation of cyclodextrin-drug conjugate using TDA analysis |
| 00:24:04 | Summary |
| 00:24:42 | Any questions? |
| 00:24:51 | Thank you for your attentionAny questions? |
| 00:32:21 | Thank You! |
Viscosizer TD is a key component of Malvern’s biopharmaceutical toolset, offering novel capabilities for biophysical characterization in complex solutions, particularly applicable in the early stages of the biopharmaceutical development workflow.
Viscosizer TD provides an orthogonal technique for characterization of molecular size, solution stability and self- association, as well as relative viscosity. Industrial researchers compiling predictive molecular stability profiles for early developability assessment must extrapolate the long-term stability behavior of therapeutic molecules from initial data in order to reduce development risk and cost. The fully-automated Viscosizer TD requires low sample volumes and provides a multivariate dataset output, enabling a more efficient and informed decision-making process.
演讲嘉宾
Dr. Hiteshri Makwana is a Product Manager for the Formulation Sciences (Biologics) sector, within Malvern PANalytical's Bioscience Business Development team. Hiteshri previously worked for Abzena in Cambridge as a Senior Bioconjugation Scientist, using cutting-edge conjugation technology to develop site-specific antibody-drug conjugates as targeted entities for cancer therapy. Hiteshri obtained a Ph.D. from the School of Pharmacy, University of Nottingham, and her thesis was entitled ‘Development of nanoscaled protein-polymer constructs towards novel therapeutic applications’. Hiteshri’s PhD was a joint project with Novozymes Biopharma and involved an element of commercial work with investigations into the business development and marketing strategies required for protein-based therapies.
Dr. Markos Trikeriotis studied Chemistry at the University of Crete, Greece, where he also completed his PhD in Biochemistry, investigating the use of inorganic materials in drug delivery applications. He then moved to Cornell University, USA, as a post-doctoral associate, where he studied the applications of metal oxide nanoparticles in lithographic nano-patterning. Markos worked for a biotechnology start-up in Cardiff, UK and then joined the Microviscometry team at Malvern PANalytical as an Applications Development Scientist.
更多信息
What will you learn?
This webinar will help the viewer to:
• Understand the value and applicability of Taylor Dispersion Analysis & Microcapillary Viscometry
• Demonstrate applicability of the Viscosizer TD with case studies - overview of published data
• Appreciate the value of applying and understanding self-association behavior (interaction parameter (kD)) from early onset as an integral part of the stability profiling dataset
Who should attend?
Scientists working in early-stage development within the Biopharmaceutical industry. Those interested in assessing molecular size, stability and self-association, as well as relative viscosity of proteins, peptides and small molecules. Also, those who require protein characterization techniques using ultra-low sample volumes, during lead candidate selection.
Job titles include:
• Research/senior research scientist
• Formulation scientists
• Group/team leader
• Ph.D. students
• Post-doctoral research associate
• Lab technician
• Lab manager